Company
Recursion Pharmaceuticals
Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
What it is
Recursion (NASDAQ: RXRX) uses very-high-throughput cellular imaging (millions of images per week) combined with machine learning to map cellular responses to small molecules across multiple disease contexts. The approach generates large datasets that are then mined for candidate drugs across many indications simultaneously.
Pipeline
Spans cancer, rare disease, and inflammation. Aging-relevant programmes include senescence-related pre-clinical work; specifics evolve with quarterly updates.
Strategic move
In 2023 Recursion announced acquisition of Exscientia, another AI-drug-discovery company, consolidating the largest AI-first biotech.
NVIDIA invested in 2023; partnership with Roche, Bayer, and others.
Why it’s in this reference
Recursion is the most-public example of the AI-bio investment wave that also produced Insilico Medicine, Spring Discovery, NewLimit, and others. The thesis: ML-enabled phenotypic discovery finds drugs that target-based approaches miss.
Whether AI-bio delivers proportional clinical wins remains an open question that the next 5–10 years will answer.